5ja7: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914== | ==Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914== | ||
<StructureSection load='5ja7' size='340' side='right' caption='[[5ja7]], [[Resolution|resolution]] 1.61Å' scene=''> | <StructureSection load='5ja7' size='340' side='right'caption='[[5ja7]], [[Resolution|resolution]] 1.61Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5ja7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JA7 OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[5ja7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JA7 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5JA7 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6HM:[([1,1-BIPHENYL]-2-YL)METHYL]PROPANEDIOIC+ACID'>6HM</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6HM:[([1,1-BIPHENYL]-2-YL)METHYL]PROPANEDIOIC+ACID'>6HM</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CTSK, CTSO, CTSO2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cathepsin_K Cathepsin K], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.38 3.4.22.38] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cathepsin_K Cathepsin K], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.38 3.4.22.38] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5ja7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ja7 OCA], [http://pdbe.org/5ja7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ja7 RCSB], [http://www.ebi.ac.uk/pdbsum/5ja7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ja7 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
| Line 21: | Line 22: | ||
</div> | </div> | ||
<div class="pdbe-citations 5ja7" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5ja7" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Cathepsin 3D structures|Cathepsin 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 26: | Line 30: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Cathepsin K]] | [[Category: Cathepsin K]] | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Korenc, M]] | [[Category: Korenc, M]] | ||
[[Category: Lenarcic, B]] | [[Category: Lenarcic, B]] | ||
Revision as of 10:39, 10 June 2020
Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914
Structural highlights
Disease[CATK_HUMAN] Defects in CTSK are the cause of pycnodysostosis (PKND) [MIM:265800]. PKND is an autosomal recessive osteochondrodysplasia characterized by osteosclerosis and short stature.[1] [2] [3] [4] Function[CATK_HUMAN] Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Publication Abstract from PubMedThe cysteine peptidase cathepsin K is a potent collagenolytic enzyme and a promising target for the treatment of osteoporosis. Here, we characterize its allosteric fine-tuning via a recently identified allosteric site. We show that compound NSC94914 binds this site and acts as a specific partial inhibitor of the collagenolytic activity of cathepsin K. We link the functional differences between NSC94914 and known effectors (compound NSC11345 and glycosaminoglycans) to their different modes of interaction with the site. We characterize the allosteric site by site-directed mutagenesis and show that it is involved in specific regulation of the collagenolytic activity of cathepsin K. An allosteric site enables fine-tuning of cathepsin K by diverse effectors.,Novinec M, Rebernik M, Lenarcic B FEBS Lett. 2016 Nov 17. doi: 10.1002/1873-3468.12495. PMID:27859061[5] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||